Clinical Trials Journal 1986;23(4):242-248

News provided by Eli Lilly and Company May 28, 2026, 13:00 ET Phase 3 ACHIEVE results showed Foundayo, an oral GLP-1 taken without food or water restrictions, outperformed oral semaglutide and dapagliflozin in type 2 diabetes, reinforcing its potential to redefine oral incretin therapy New analyses of the ATTAIN program highlight Foundayo' s profile in patient populations central to the future of cardiometabolic care, including women at every stage of menopause Pivotal Phase 3 results showed retatrutide, a first-in-class triple receptor agonist, delivered powerful results in obesity, type 2 diabetes and other complications INDIANAPOLIS, May 28, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide), Mounjaro (tirzepatide), Foundayo (orforglipron) and retatrutide, will present new data across its cardiometabolic portfolio at the American Diabetes Association's 86th Scientific Sessions taking place June 5-8 in New Orleans

How to Get an Oral Semaglutide Prescription Online in Alabama Wondering "how to get oral semaglutide for weight loss"
Superior to both semaglutide alone and cagrilintide alone
Benefits of Semaglutide In this section, we will provide an overview of the benefits of semaglutide, a drug that has demonstrated safety and effectiveness in a range of indications